(Q36951998)

17 August 2017

1 reference

title

Immunoglobulin E blockade in the treatment of asthma (English)

1 reference

17 August 2017

1 reference

Robert Kuhn

1

1 reference

17 August 2017

language of work or name

English

0 references

publication date

1 October 2007

1 reference

17 August 2017

1 reference

17 August 2017

volume

27

1 reference

17 August 2017

issue

10

1 reference

17 August 2017

page(s)

1412-1424

1 reference

Design and baseline characteristics of the epidemiology and natural history of asthma: Outcomes and Treatment Regimens (TENOR) study: a large cohort of patients with severe or difficult-to-treat asthma

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.10.1412

Inhaled corticosteroids for asthma therapy: patient compliance, devices, and inhalation technique

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.10.1412

Measurement of children's asthma medication adherence by self report, mother report, canister weight, and Doser CT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.10.1412

Modifiable barriers to adherence to inhaled steroids among adults with asthma: it's not just black and white

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.10.1412

Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.10.1412

Gastroesophageal reflux: a potential asthma trigger

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.10.1412

Infectious triggers of asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.10.1412

Rhinosinusitis and pediatric asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.10.1412

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.10.1412

The effects of outdoor air pollution and tobacco smoke on asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.10.1412

Comparison of a beta 2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.10.1412

Effect of long-term treatment with an inhaled corticosteroid (budesonide) on airway hyperresponsiveness and clinical asthma in nonsteroid-dependent asthmatics

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.10.1412

Inhaled corticosteroids: impact on asthma morbidity and mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.10.1412

Significant variability in response to inhaled corticosteroids for persistent asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.10.1412

Doubling the dose of budesonide versus maintenance treatment in asthma exacerbations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.10.1412

Dose-response relationship of inhaled budesonide in adult asthma: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.10.1412

Oral candidiasis associated with inhaled corticosteroid use: comparison of fluticasone and beclomethasone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.10.1412

Effects of inhaled corticosteroids on bone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.10.1412

Inhaled corticosteroids and hip fracture: a population-based case-control study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.10.1412

Inhaled corticosteroids: past lessons and future issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.10.1412

Hypothalamo-pituitary-adrenal axis suppression in asthmatics inhaling high dose corticosteroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.10.1412

Systemic adverse effects of inhaled corticosteroid therapy: A systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.10.1412

The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.10.1412

Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.10.1412

Therapeutic modulation of allergic airways disease with leukotriene receptor antagonists.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.10.1412

Cysteinyl leukotrienes in allergic inflammation: strategic target for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.10.1412

Anti-leukotrienes as add-on therapy to inhaled glucocorticoids in patients with asthma: systematic review of current evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.10.1412

Response profiles to fluticasone and montelukast in mild-to-moderate persistent childhood asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.10.1412

Long-acting bronchodilator or leukotriene modifier as add-on therapy to inhaled corticosteroids in persistent asthma?

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.10.1412

Effect of long-term treatment with inhaled budesonide or theophylline on lung function, airway reactivity and asthma symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.10.1412

Comparison of inhaled corticosteroid combined with theophylline and double-dose inhaled corticosteroid in moderate to severe asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.10.1412

Comparison of second controller medications in addition to inhaled corticosteroid in patients with moderate asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.10.1412

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.10.1412

Targeting the IgE molecule in allergic and asthmatic diseases: review of the IgE molecule and clinical efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.10.1412

Inflammation in allergic asthma: initiating events, immunological response and risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.10.1412

IgE enhances mouse mast cell Fc(epsilon)RI expression in vitro and in vivo: evidence for a novel amplification mechanism in IgE-dependent reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.10.1412

Signalling through the high-affinity IgE receptor Fc epsilonRI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.10.1412

Total serum IgE is associated with asthma independently of specific IgE levels. The Spanish Group of the European Study of Asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.10.1412

Total serum IgE levels in a large cohort of patients with severe or difficult-to-treat asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.10.1412

Total serum IgE concentrations in adolescents and adults using the phadebas IgE PRIST technique.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.10.1412

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.10.1412

Problems in defining normal limits for serum IgE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.10.1412

Role and interpretation of total serum IgE measurements in the diagnosis of allergic airway disease in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.10.1412

Omalizumab rapidly decreases nasal allergic response and FcepsilonRI on basophils.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.10.1412

Omalizumab-induced reductions in mast cell Fce psilon RI expression and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.10.1412

Omalizumab treatment downregulates dendritic cell FcepsilonRI expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.10.1412

Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.10.1412

The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.10.1412

Omalizumab is effective in the long-term control of severe allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.10.1412

Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.10.1412

Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.10.1412

Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.10.1412

Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.10.1412

Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.10.1412

Efficacy of omalizumab, an anti-immunoglobulin E antibody, in patients with allergic asthma at high risk of serious asthma-related morbidity and mortality.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.10.1412

Omalizumab, a recombinant humanized anti-IgE antibody, reduces asthma-related emergency room visits and hospitalizations in patients with allergic asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.10.1412

The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.10.1412

The anti-IgE antibody omalizumab improves asthma-related quality of life in patients with allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.10.1412

Impact of omalizumab on quality-of-life outcomes in patients with moderate-to-severe allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.10.1412

Immunological and clinical changes in allergic asthmatics following treatment with omalizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.10.1412

Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.10.1412

Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.10.1412

Effects of omalizumab and budesonide on markers of inflammation in human bronchial epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.10.1412

Anti-IgE (omalizumab) inhibits late-phase reactions and inflammatory cells after repeat skin allergen challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.10.1412

Safety and tolerability of omalizumab (Xolair), a recombinant humanized monoclonal anti-IgE antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.10.1412

21 January 2018

Omalizumab for asthma

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.10.1412

Cost-effectiveness analysis of omalizumab in adults and adolescents with moderate-to-severe allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.10.1412

21 January 2018

Identifiers

DOI

10.1592/PHCO.27.10.1412

1 reference

17 August 2017

1 reference